Silence Therapeutics (SLN) to Announce Quarterly Earnings on Thursday

Silence Therapeutics (NASDAQ:SLN) is anticipated to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Silence Therapeutics to post earnings of ($0.1387) per share and revenue of $1.1680 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 2:00 AM ET.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14). The company had revenue of $0.42 million for the quarter, compared to analyst estimates of $1.25 million. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%. On average, analysts expect Silence Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Silence Therapeutics Stock Performance

Silence Therapeutics stock opened at $11.55 on Thursday. The company’s 50 day simple moving average is $8.66 and its 200-day simple moving average is $6.90. The company has a market capitalization of $545.62 million, a price-to-earnings ratio of -7.26 and a beta of 1.38. Silence Therapeutics has a 1 year low of $4.19 and a 1 year high of $12.19.

Institutional Trading of Silence Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in shares of Silence Therapeutics during the fourth quarter worth about $71,000. Massar Capital Management LP acquired a new position in shares of Silence Therapeutics in the second quarter valued at approximately $115,000. Citadel Advisors LLC purchased a new stake in Silence Therapeutics during the 3rd quarter worth approximately $112,000. ADAR1 Capital Management LLC increased its stake in Silence Therapeutics by 26.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock worth $144,000 after buying an additional 5,000 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Silence Therapeutics during the 4th quarter worth approximately $177,000. 98.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on SLN shares. Cantor Fitzgerald began coverage on shares of Silence Therapeutics in a research report on Wednesday, June 24th. They set an “overweight” rating for the company. HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research report on Wednesday, June 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Silence Therapeutics has an average rating of “Moderate Buy” and an average target price of $55.00.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.